Eculizumab (Soliris®)

Assessment Status Assessment process complete
Drug Eculizumab
Brand Soliris®
Indication For the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in the Irish healthcare setting.
Assessment Process
Rapid review commissioned 20/01/2010
Rapid review completed 20/03/2010
Rapid review outcome Reimbursement not recommended
NCPE assessment re-commenced 15/07/2013
NCPE assessment completed 14/10/2013
NCPE assessment outcome Reimbursement not recommended.

Alexion Pharma UK. Ltd have failed to demonstrate the cost-effectiveness of eculizumab  (Soliris®) for the treatment of PNH in the Irish healthcare setting.

Technical Summary 2010

Pharmacoeconomic Reassessment

The NCPE do not believe that eculizumab (Soliris®) is value for money for the treatment of patients with PNH in the Irish Healthcare setting

Technical Summary-2013